Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefamandole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.87 |
| ▸ | POLB | P06746 | 10/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | HPGD | P15428 | 1/20 | 0.87 |
| ▸ | APEX1 | P27695 | 1/20 | 0.87 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.77 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefamandole SCHEMBL28121696 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL4401823 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL11883501 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL17131900 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL37287 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL10478382 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL14509205 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL16072810 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL10478386 | 1.00 | SLC22A6 (1.00) | SLC22A6SLC22A8SLC22A11NR1I2PGR | |
| Cefamandole SCHEMBL11735916 | 0.99 | SLC22A6 (0.98) | SLC22A6SLC22A8SLC22A11NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272939-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase | YALE UNIVERSITY (US) | 2015-10-01 | — | — | US | disclosed |
| EP-0083032-B1 | RECTALLY ADMINISTRABLE SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT | MERCK & CO. INC. (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4470980-A | Method of increasing oral absorption of β-lactam antibiotics | INTERX RESEARCH CORP. (US) | 1984-09-11 | — | — | US | disclosed |
| US-4406896-A | ANTIBIOTICS, ACIDS, HYDROXY | MERCK & CO., INC. (US) | 1983-09-27 | — | — | US | disclosed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272939-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase | KDM1B, KDM1A, JMJD1C | SLC22A6 4271/4885SLC22A8 4774/4885SLC22A11 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.